AbCellera Biologics Inc. is a Vancouver, British Columbia-based biotechnology company that discovers and develops antibody therapeutics. The company is best known for its leading role in the Pandemic Prevention Platform, a project of DARPA's Biological Technologies Office. AbCellera utilizes a proprietary technology platform, which they claim can develop "medical countermeasures within 60 days." Its platform for single-cell screening was initially developed at the University of British Columbia.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| ABCL | AbCellera Biologics Inc. | 2025-12-02 08:25:25 | 3.52 | 0.05 | 1.45 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ABCL | 0001703057 | AbCellera Biologics Inc. | CA00288U1066 | 9845000861BC95FF9F73 | — | Nasdaq | 2834 | Pharmaceutical Preparations | 1231 | A1 | 150 W 4TH AVENUE | VANCOUVER | A1 | V5Y 1G6 | CANADA | CA | (604) 559-9005 | 150 W 4TH AVENUE, VANCOUVER, A1, V5Y 1G6 | 150 W 4TH AVENUE, VANCOUVER, A1, V5Y 1G6 | — | Biotechnology | 2012 | — | 596 | http://abcellera.com | 670,873,681 | 299,011,566 | 299,335,048 | AbCellera Biologics Inc. is a Vancouver, British Columbia-based biotechnology company that discovers and develops antibody therapeutics. The company is best known for its leading role in the Pandemic Prevention Platform, a project of DARPA's Biological Technologies Office. AbCellera utilizes a proprietary technology platform, which they claim can develop "medical countermeasures within 60 days." Its platform for single-cell screening was initially developed at the University of British Columbia. | 2025-11-27 17:10:47 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2024 | 670,873,681 | -792,962,771 | -54.1702 | 297,987,669 | 5,205,517 | 1.7779 |
| 2023 | 1,463,836,452 | -2,403,087,795,548 | -99.9391 | 292,782,152 | 5,095,953 | 1.7714 |
| 2022 | 2,404,551,632,000 | -1,390,437,522,000 | -36.6388 | 287,686,199 | 3,762,417 | 1.3252 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Véronique Lecault | Chief Technology Officer | 2024 | 460,000 | 184,666 | — | — | 23,040 | 3,424,564 |
| Tryn Stimart | Chief Legal Officer, Chief Compliance Officer, Corporate Secretary | 2024 | 460,000 | 194,580 | — | — | 30,500 | 2,890,567 |
| Carl L.G. Hansen, Ph.D. | Chief Executive Officer | 2024 | 460,000 | 263,840 | — | — | 22,996 | 8,245,492 |
| Andrew Booth | Chief Financial Officer | 2024 | 460,000 | 188,680 | — | — | 23,040 | 3,428,578 |
| Tryn Stimart | Chief Legal Officer, Chief Compliance Officer, Corporate Secretary | 2023 | 460,000 | 180,090 | — | — | 27,600 | 667,690 |
| Fiscal Year | Employee Count |
|---|---|
| 2024 | 596 |
| 2023 | 586 |
| 2022 | 495 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Revenue | 28,833,000 | 38,025,000 | 485,424,000 |
| Cost Of Revenue | — | — | — |
| Gross Profit | — | — | — |
| Research And Development Expenses | 167,259,000 | 175,658,000 | 107,879,000 |
| General And Administrative Expenses | 72,711,000 | 60,999,000 | 55,485,000 |
| Operating Expenses | 343,599,000 | 275,232,000 | 268,913,000 |
| Operating Income | -314,766,000 | -237,207,000 | 216,511,000 |
| Net Income | -162,857,000 | -146,398,000 | 158,519,000 |
| Earnings Per Share Basic | -0.55 | -0.51 | 0.56 |
| Earnings Per Share Diluted | -0.55 | -0.51 | 0.5 |
| Weighted Average Shares Outstanding Basic | 294,327,532 | 289,166,486 | 285,056,606 |
| Weighted Average Shares Outstanding Diluted | 294,327,532 | 289,166,486 | 314,827,255 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Cash And Cash Equivalents | 156,325,000 | 133,320,000 | 386,535,000 |
| Marketable Securities Current | — | — | — |
| Accounts Receivable | 31,980,000 | 0 | 9,300,000 |
| Inventories | — | — | — |
| Non Trade Receivables | 26,534,000 | 33,792,000 | 64,817,000 |
| Other Assets Current | 67,140,000 | 55,810,000 | 75,413,000 |
| Total Assets Current | 751,370,000 | 871,985,000 | 1,025,491,000 |
| Marketable Securities Non Current | — | — | — |
| Property Plant And Equipment | — | — | 217,255,000 |
| Other Assets Non Current | 96,538,000 | 94,244,000 | 46,331,000 |
| Total Assets Non Current | 609,183,000 | 616,109,000 | 515,416,000 |
| Total Assets | 1,360,553,000 | 1,488,094,000 | 1,540,907,000 |
| Accounts Payable | 34,350,000 | 25,509,000 | 14,828,000 |
| Deferred Revenue | 13,521,000 | 18,958,000 | 21,612,000 |
| Short Term Debt | — | — | — |
| Other Liabilities Current | — | — | 0 |
| Total Liabilities Current | 76,612,000 | 119,013,000 | 118,320,000 |
| Long Term Debt | — | — | — |
| Other Liabilities Non Current | 1,469,000 | 5,906,000 | 3,086,000 |
| Total Liabilities Non Current | 227,857,000 | 216,763,000 | 189,310,000 |
| Total Liabilities | 304,469,000 | 335,776,000 | 307,630,000 |
| Common Stock | 777,171,000 | 753,199,000 | 734,365,000 |
| Retained Earnings | 116,930,000 | 279,787,000 | 426,185,000 |
| Accumulated Other Comprehensive Income | -4,378,000 | -1,720,000 | -1,391,000 |
| Total Shareholders Equity | 1,056,084,000 | 1,152,318,000 | 1,233,277,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Depreciation And Amortization | 90,850,000 | 24,395,000 | 27,843,000 |
| Share Based Compensation Expense | 67,581,000 | 64,183,000 | 49,481,000 |
| Other Non Cash Income Expense | 19,708,000 | -277,000 | -8,547,000 |
| Change In Accounts Receivable | 75,119,000 | 45,933,000 | 22,715,000 |
| Change In Inventories | — | — | — |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | -5,954,000 | -8,980,000 | — |
| Change In Accounts Payable | 10,635,000 | — | — |
| Change In Other Liabilities | — | — | -1,689,000 |
| Cash From Operating Activities | -108,556,000 | -43,877,000 | 277,360,000 |
| Purchases Of Marketable Securities | 765,086,000 | 1,021,510,000 | 763,982,000 |
| Sales Of Marketable Securities | 937,882,000 | 910,937,000 | 510,631,000 |
| Acquisition Of Property Plant And Equipment | 78,396,000 | 76,947,000 | 70,660,000 |
| Acquisition Of Business | — | 0 | — |
| Other Investing Activities | — | — | — |
| Cash From Investing Activities | 121,409,000 | -221,108,000 | -352,625,000 |
| Tax Withholding For Share Based Compensation | — | — | — |
| Payments Of Dividends | 0 | 0 | 0 |
| Issuance Of Common Stock | — | — | — |
| Repurchase Of Common Stock | — | — | — |
| Issuance Of Long Term Debt | — | — | — |
| Repayment Of Long Term Debt | — | — | — |
| Other Financing Activities | — | — | — |
| Cash From Financing Activities | 12,769,000 | 10,356,000 | -1,628,000 |
| Change In Cash | 23,005,000 | -254,040,000 | -86,492,000 |
| Cash At End Of Period | 156,325,000 | 133,320,000 | 386,535,000 |
| Income Taxes Paid | — | — | — |
| Interest Paid | — | — | — |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Earnings Per Share | -0.55 | -0.51 | 0.56 |
| Price To Earnings Ratio | -5.3273 | -11.1961 | 18.0893 |
| Earnings Growth Rate | 7.8431 | -191.0714 | 0 |
| Price Earnings To Growth Ratio | -0.6792 | 0.0586 | — |
| Book Value Per Share | 3.5881 | 3.985 | 4.3264 |
| Price To Book Ratio | 0.8166 | 1.4329 | 2.3414 |
| Ebitda | -72,007,000 | -122,003,000 | 186,362,000 |
| Enterprise Value | — | — | — |
| Dividend Yield | 0 | 0 | 0 |
| Dividend Payout Ratio | 0 | 0 | 0 |
| Debt To Equity Ratio | — | — | — |
| Capital Expenditures | — | — | 133,482,000 |
| Free Cash Flow | — | — | 143,878,000 |
| Return On Equity | -0.1542 | -0.127 | 0.1285 |
| One Year Beta | 1.2927 | 1.3006 | 1.3545 |
| Three Year Beta | 1.3212 | 1.2268 | 1.2009 |
| Five Year Beta | 1.2287 | 1.2204 | 1.2009 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| Montalbano John S. | Director | 2025-11-26 | 50,000 | A | 221,000 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| Lantern Wealth Advisors, LLC | 2025-09-30 | 75,450 | 15,000 | 5.03 |
| JPMORGAN CHASE & CO | 2025-09-30 | 657,239 | 130,664 | 5.03 |
| Advisory Services Network, LLC | 2025-09-30 | 132,179 | 26,278 | 5.03 |
| CAXTON ASSOCIATES LLP | 2025-09-30 | 1,798,255 | 357,506 | 5.03 |
| KESTRA PRIVATE WEALTH SERVICES, LLC | 2025-09-30 | 59,354 | 11,800 | 5.03 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| FundVantage Trust | 2025-09-30 | Institutional Class | GENIX | 1 | -225,463.89 | -0.0574 |
| FundVantage Trust | 2025-09-30 | Institutional Class | GONIX | 1 | -60,083.89 | -0.0548 |
| FundVantage Trust | 2025-09-30 | Institutional Class | GARIX | 1 | -470,346.23 | -0.0484 |
| iSHARES TRUST | 2025-09-30 | iShares Biotechnology ETF | IBB | 1,329,170 | 6,685,725.1 | 0.1125 |
| SPDR INDEX SHARES FUNDS | 2025-09-30 | SPDR(R) S&P(R) International Small Cap ETF | GWX | 163,492 | 822,364.76 | 0.1039 |